[14] Recently, functional neuroimaging suggested that the bladder is under tonic influence of the brain.[15, 16] Parkinson’s disease and stroke are one of the major neurologic disorders, and they also cause bladder dysfunction.[17, 18] Although the frequency of bladder dysfunction in depression is lower (up to 25.9%) than that in Parkinson’s disease (up to 75%) and stroke (up to 55%), it is significantly higher than that in age-matched

controls (10%).[17-19] Therefore, depression/anxiety Ku-0059436 nmr can be regarded as an important cause of bladder dysfunction, although the detailed mechanism of the causation remains unclear. In this review, we performed a systematic review of the literature to identify the frequency, lower urinary tract symptoms, urodynamic findings, putative underlying pathology, and management of bladder dysfunction in patients with Navitoclax supplier depression/anxiety. Although lower urinary tract symptoms (LUTS) have been described in major depression,[6-8] ,[11-13], [20] it is difficult to determine to what extent depression is a contributing factor. Lower urinary tract symptoms are common in the general population.[21] Men aged 60 or older may have benign prostatic hyperplasia.[22] Women may have physical stress-induced urinary incontinence. In addition, neurologic diseases might contribute to LUTS. For instance, OAB occurs in persons older than 65 due, in part, to latent

brain ischemia.[23] Peripheral factors for LUTS include metabolic syndrome, diabetes, dyslipidemia, hypertension, and smoking, all of which are relevant to atherosclerosis.[24, 25] To overcome these problems, patient recruitment with no selective bias, together with community-based control subjects, is needed. In a recent study by Ito et al.[19] 224 depressive patients (97 men and 127 women, aged 42 [14–80] years, Alectinib order illness duration 2.2 years [1 week to 40 years], all visiting a university psychiatry clinic) and 391 healthy control subjects (271 men and 120 women, age

48 [30–69] years, all undergoing an annual health survey) were recruited. The 224 depressive patients were subdivided into 128 patients who had not received any medication (drug-naïve group; 61 men, 67 women; age 40.3 [14–80] years, illness duration 1.7 [1 week to 40 years] years), and 96 patients who were referred from primary care physicians and had already received medication (medicated group; 36 men, 60 women; age 43.5 [15–79] years; illness duration 2.8 [1 week to 15 years] years). The results of the study showed that the LUTS questionnaire scores of the drug-naïve depression group (up to 25.9%) were significantly higher (P < 0.01, 0.05) than that in the control group around 10% (Fig. 1) (medicated group appears later). The majority of the depressive patients experienced the onset of LUTS at around the same time, either with or after the appearance of an affective disorder. None had a history of pelvic organ surgery, or symptoms of neurologic disorder such as stroke, Parkinson’s disease or diabetes.